ArticleJTO clinical and research reports2022

Real-World Treatment Patterns and Outcomes Among Patients With Metastatic NSCLC Previously Treated With Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Inhibitors.

Savreet Bains et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.